Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective and Multicenter Clinical Study to Identify the Molecular Characterization and Subtypes in Patients With HER2-positive Breast Cancer Receiving Neoadjuvant Trastuzumab and Pertuzumab.

NCT07187752 is registered in ClinicalTrials.gov with Shandong Cancer Hospital and Institute as lead sponsor.

NCT NCT07187752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07187752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective and Multicenter Clinical Study to Identify the Molecular Characterization and Subtypes in Patients With HER2-positive Breast Cancer Receiving Neoadjuvant Trastuzumab and Pertuzumab.
Lead sponsor
Shandong Cancer Hospital and Institute
Phase
Not applicable
Overall status
Not yet recruiting
Start date
September 30, 2025
Completion date
June 30, 2027
Enrollment
1,039 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer